Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Depreciation & Amortization (CF): 2010-2025

Historic Depreciation & Amortization (CF) for Ani Pharmaceuticals (ANIP) over the last 16 years, with Sep 2025 value amounting to $22.6 million.

  • Ani Pharmaceuticals' Depreciation & Amortization (CF) rose 43.71% to $22.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $91.4 million, marking a year-over-year increase of 51.52%. This contributed to the annual value of $67.7 million for FY2024, which is 13.28% up from last year.
  • According to the latest figures from Q3 2025, Ani Pharmaceuticals' Depreciation & Amortization (CF) is $22.6 million, which was down 2.79% from $23.3 million recorded in Q2 2025.
  • Over the past 5 years, Ani Pharmaceuticals' Depreciation & Amortization (CF) peaked at $23.3 million during Q2 2025, and registered a low of $10.9 million during Q1 2021.
  • Over the past 3 years, Ani Pharmaceuticals' median Depreciation & Amortization (CF) value was $15.2 million (recorded in 2023), while the average stood at $17.8 million.
  • In the last 5 years, Ani Pharmaceuticals' Depreciation & Amortization (CF) declined by 2.55% in 2021 and then soared by 58.41% in 2025.
  • Ani Pharmaceuticals' Depreciation & Amortization (CF) (Quarterly) stood at $13.7 million in 2021, then climbed by 13.80% to $15.6 million in 2022, then dropped by 2.43% to $15.2 million in 2023, then skyrocketed by 48.74% to $22.6 million in 2024, then surged by 43.71% to $22.6 million in 2025.
  • Its last three reported values are $22.6 million in Q3 2025, $23.3 million for Q2 2025, and $22.9 million during Q1 2025.